FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathy

Research that was carried out by Baylor College of Medicine and Texas Children’s Hospital doctors has led to the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to a treatment for developmental and epileptic encephalopathy (DEE) due to syntaxin-binding protein 1 (STXBP1) mutations.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup